Literature DB >> 22030186

Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis.

Aaron M Burnett1, Christopher P Anderson, Michael D Zwank.   

Abstract

OBJECTIVE: The aim of this study was to determine the rates of laboratory confirmed gonorrhea (GC) and chlamydia (CT) in emergency department (ED) patients with pelvic inflammatory disease (PID) and cervicitis who were diagnosed clinically and treated empirically. A secondary goal examines which clinical criteria were present in patients with PID testing positive for GC/CT.
METHODS: We conducted a retrospective chart review of all ED patents diagnosed with PID or cervicitis during a 40-month period (January 2007-March 2010). Charts were reviewed for laboratory-confirmed GC or CT. For patients with positive GC or CT studies, the presence of key clinical criteria used in the diagnosis of PID was tallied.
RESULTS: A total of 1469 patients were diagnosed with cervicitis and 343 with PID. Of these patients, 27 (1.8%) of 1469 and 15 (4.4%) of 343 were GC positive, and 136 (9.3%) of 1469 and 34 (10%) of 343 were CT positive. Twenty-six cervicitis (1.8%) and 9 PID (2.6%) patients were positive for both infections. One hundred eighty-nine cervicitis (13%) and 58 PID (17%) patients were positive for at least 1 sexually transmitted infection. Of the 58 patients with PID with laboratory-confirmed GC/CT, the following clinical criteria were present: abdominal pain, 58 of 58; abdominal tenderness, 50 of 58; cervical discharge, 47 of 58; cervical motion tenderness, 46 of 58; adnexal tenderness, 32 of 58; vaginal bleeding, 8 of 58; and fever, 2 of 58. Ultrasound was preformed in 27 (47%) of 58 GC/CT-positive patients with PID, with findings suggestive of PID in 12 (44%) of 27 ultrasounds. One hundred percent of abnormal ultrasounds were associated with positive GC and/or CT results.
CONCLUSION: There is a generally low prevalence of GC and CT in this patient population diagnosed with cervicitis or PID. There is a very low prevalence of coinfection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22030186     DOI: 10.1016/j.ajem.2011.07.014

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  11 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae.

Authors:  Marwa Alhashimi; Abdelrahman Mayhoub; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

3.  Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents.

Authors:  Melinda A B Petrina; Lisa A Cosentino; Harold C Wiesenfeld; Toni Darville; Sharon L Hillier
Journal:  Anaerobe       Date:  2019-02-10       Impact factor: 3.331

4.  Management of Pelvic Inflammatory Disease in Selected U.S. Sexually Transmitted Disease Clinics: Sexually Transmitted Disease Surveillance Network, January 2010-December 2011.

Authors:  Eloisa Llata; Kyle T Bernstein; Roxanne P Kerani; Preeti Pathela; Jane R Schwebke; Christina Schumacher; Mark Stenger; Hillard S Weinstock
Journal:  Sex Transm Dis       Date:  2015-08       Impact factor: 2.830

5.  Antibacterial Activity of Chitosan Nanoparticles Against Pathogenic N. gonorrhoea.

Authors:  Fulwah Alqahtani; Fadilah Aleanizy; Eram El Tahir; Hiba Alhabib; Raghad Alsaif; Gamal Shazly; Hajar AlQahtani; Ibrahim Alsarra; Jafar Mahdavi
Journal:  Int J Nanomedicine       Date:  2020-10-13

6.  In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.

Authors:  Nader S Abutaleb; Ahmed E M Elhassanny; Mohamed N Seleem
Journal:  Microb Pathog       Date:  2022-02-19       Impact factor: 3.738

7.  A Novel Platform Using RNA Signatures To Accelerate Antimicrobial Susceptibility Testing in Neisseria gonorrhoeae.

Authors:  Marjan M Hashemi; Nikhil Ram-Mohan; Xi Yang; Nadya Andini; Nicholas R Gessner; Karen C Carroll; Tza-Huei Wang; Samuel Yang
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

8.  Chinese Herbal Formula Feilin Vaginal Gel Prevents the Cervicitis in Mouse Model.

Authors:  Xin Mao; Ronghua Zhao; Rongmei Yao; Shanshan Guo; Lei Bao; Yingjie Gao; Jing Sun; Yanyan Bao; Yujing Shi; Xiaolan Cui
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-10       Impact factor: 2.629

9.  Streptococcus constellatus Peritonitis and Subsequent Septic Shock following Intrauterine Device Removal.

Authors:  Joan Tymon-Rosario; Jessica M Atrio; Hyun Ah Yoon; David Erlichman; Veronica Lerner
Journal:  Case Rep Obstet Gynecol       Date:  2019-08-04

Review 10.  Current perspectives in the USA on the diagnosis and treatment of pelvic inflammatory disease in adolescents.

Authors:  William L Risser; Jan M Risser; Amanda L Risser
Journal:  Adolesc Health Med Ther       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.